Scientific Review Committee (SRC)

A Scientific Review Committee (SRC) is an institutional committee that evaluates the scientific merit and feasibility of a research protocol — study rationale, design, statistical plan, and likelihood of accrual — separately from and, in most institutions that use one, before the protocol reaches the Institutional Review Board (IRB) for ethical review. SRCs are most common at NCI-designated cancer centers, where the National Cancer Institute (NCI) requires a documented scientific-review step as a condition of Cancer Center Support Grant (CCSG/P30) funding. The requirement is distinctly oncology-specific: outside cancer research, most institutions route protocols directly to the IRB with no separate scientific-review body in between.

What the SRC actually reviews

An SRC’s review is confined to scientific questions, not ethical or human-subjects-protection questions. Published descriptions of institutional scientific review consistently list the same core criteria: originality, scientific rationale and background, study design and methodology, statistical plan and analytic approach, feasibility (including realistic accrual projections against the patient population actually available), and institutional or portfolio prioritization — whether the study duplicates or competes with other open protocols for the same patient population. Some SRCs are organized as multi-disciplinary subcommittees drawing on biostatistics, pharmacy, clinical trial design, and disease-specific oncology expertise to conduct that review.

SRC vs. IRB: scientific merit vs. ethical review

The distinction is functional, not just procedural. The IRB’s jurisdiction, under the Common Rule (45 CFR 46) and, for FDA-regulated studies, 21 CFR Part 56, is human-subjects protection: informed consent, risk-benefit balance for participants, privacy and confidentiality safeguards, and equitable subject selection. An IRB does not evaluate whether a study is scientifically well-designed or worth doing in the first place — that is exactly the gap an SRC is built to fill. At institutions with a mandated SRC, a protocol must clear both reviews before enrollment can begin, and in the NCI model the SRC review is sequenced first: the protocol is reviewed for scientific merit, and only a protocol the SRC has approved is forwarded to the IRB. A weak or duplicative study can be stopped at the SRC stage without ever consuming IRB review capacity on ethical questions that only matter if the science is sound enough to proceed.

SRC vs. DSMB/DMC: upfront protocol review vs. ongoing safety monitoring

A Scientific Review Committee and a Data and Safety Monitoring Board (DSMB, sometimes called a Data Monitoring Committee, DMC) are frequently confused because both sit outside the investigator’s own team and both touch on a study’s scientific validity — but they operate at different points in the study lifecycle and answer different questions.

• SRC: reviews the protocol before it opens (or, in ongoing-portfolio models, at defined progress checkpoints) to decide whether the study is scientifically sound and worth activating. It is a one-time (or periodic-progress) merit gate, not a continuous monitoring function.
• DSMB/DMC: an independent body, external to the study team, that reviews accumulating trial data at regular intervals after the study has opened — adverse events, efficacy endpoints, and data completeness — and can recommend continuing, modifying, or stopping a trial on safety or futility grounds. NIH’s 1998 Policy for Data and Safety Monitoring establishes that a DSMB is generally required for multi-site trials with substantial participant risk, most notably Phase III trials, and explicitly frames data-and-safety-monitoring oversight as distinct from the requirement for IRB review and approval — the same separation-of-function logic that distinguishes an SRC from an IRB also distinguishes a DSMB from an SRC.

Put simply: the SRC asks “should this trial be allowed to start, as designed?” The IRB asks “does this trial adequately protect the people enrolled in it?” The DSMB/DMC asks, on an ongoing basis once the trial is running, “does the accumulating data mean this trial should continue as planned, be modified, or stop?” A protocol can pass SRC and IRB review and still be halted later by a DSMB if the safety or efficacy picture changes after enrollment begins.

Where the SRC sits inside NCI’s Protocol Review and Monitoring System (PRMS)

At NCI-designated cancer centers, the SRC is typically one component of a broader, NCI-mandated Protocol Review and Monitoring System (PRMS) required under the Cancer Center Support Grant program. A commonly described PRMS structure includes three parts: a Clinical Investigators Meeting (an open forum where a proposed protocol is first presented and discussed), the SRC itself (formal peer review of scientific merit prior to IRB submission), and an ongoing Protocol and Data Monitoring Committee (PDMC) that tracks accrual, safety, and scientific progress on protocols that are already open. That ongoing PDMC function is institution-level portfolio monitoring, not the same thing as a trial-specific DSMB, though the two can overlap in practice on trials that also carry an independent DSMB.

Naming varies by institution

“Scientific Review Committee” is the most common label, but institutions use several interchangeable names for the same upfront-merit-review function: Protocol Review Committee, Clinical Trial Committee, Clinical Research Committee, and (where the scientific-review and ongoing-monitoring functions are combined into a single body rather than split as under the PRMS model above) Protocol Review and Monitoring Committee (PRMC). The underlying review purpose — scientific merit and feasibility, evaluated separately from ethics — is consistent across the naming variants; the committee structure is not standardized nationally beyond the NCI requirement that a cancer center have one.

Not to be confused with NIH grant peer review

“Scientific review” also appears in a completely different context: NIH’s Center for Scientific Review coordinates peer-review study sections that evaluate grant applications for funding before an award is made. That is pre-award funding peer review of a proposal competing for a limited pool of federal grant dollars. An institutional Scientific Review Committee, by contrast, reviews an already-funded (or funding-pending) protocol’s scientific design and feasibility at the institution where it will actually be conducted, as a precondition for opening the study to enrollment. The two processes share vocabulary but serve entirely different purposes and involve different reviewers.

References

• Wolf et al., “Institutional Scientific Review of Cancer Clinical Research Protocols: A Unique Requirement That Affects Activation Timelines,” PMC (National Library of Medicine) — describes SRC/PRMC function, naming variation, and sequencing relative to IRB review.
• NIH, “NIH Policy for Data and Safety Monitoring,” NOT-98-084 (June 10, 1998), grants.nih.gov — establishes the DSMB requirement for higher-risk multi-site trials and states that data-and-safety-monitoring oversight is distinct from IRB review and approval.
• NCI Cancer Center Support Grant (P30) program guidelines, grants.nih.gov — requires NCI-designated cancer centers to maintain a Protocol Review and Monitoring System governing cancer clinical trial protocols.
• 45 CFR 46 (Common Rule), Subpart A — defines IRB jurisdiction over human-subjects research ethics review, distinct from scientific-merit review.